NAT2 catalyzes N- and O-acetylation of arylamine and heterocyclic amine substrates, functioning primarily in xenobiotic detoxification while also bioactivating certain carcinogens 1. The enzyme exhibits functional polymorphisms that produce three distinct phenotypes: rapid, intermediate, and slow acetylators, which substantially influence drug metabolism and disease susceptibility 2. Clinically, NAT2 polymorphisms associate with multiple pathologies through acetylation capacity-dependent mechanisms. The slow acetylator phenotype increases endometriosis risk 2.3-fold in Asian populations 3 and elevates prostate cancer susceptibility, with combined slow NAT2/null GSTT1/null GSTM1 genotypes increasing risk 9.64-fold 4. NAT2 slow acetylators also demonstrate increased susceptibility to anti-tuberculosis drug-induced hepatotoxicity 5 and cirrhotic portal hypertension 6. Emerging evidence indicates NAT2 transcriptional regulation by glucose and insulin suggests involvement in metabolic pathways beyond xenobiotic metabolism, with co-expression patterns correlating with lipid biosynthesis genes 7. NAT2 genotyping shows promise as a pharmacogenetic biomarker for predicting drug toxicity and disease risk, though associations with lung and colon cancer remain inconsistent 8. Ethnic variation in allele frequencies suggests population-specific disease associations warrant consideration in clinical applications.